Treatment of advanced endometrial adenocarcinoma with cyclic sequential ethinyl estradiol and medroxyprogesterone acetate.
Fifteen patients with recurrent or progressive endometrial adenocarcinoma of moderate to poor histologic differentiation were entered in a phase II trial of sequentially administered oral ethinyl estradiol and medroxyprogesterone acetate. There were no significant clinical responses in 12 patients evaluated for response and four patients experienced thromboembolic complications. This cyclic treatment regimen is considered ineffective for this patient population at the dosages and schedules used.
Tatman
J L
JL
Department of Gynecology, University of Texas M.D. Anderson Cancer Center, Houston 77030.
Freedman
R S
RS
Scott
W
W
Atkinson
E N
EN
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004997:Ethinyl Estradiol / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D013924:Thrombophlebitis / Q000139:chemically induced; D014594:Uterine Neoplasms / Q000188:drug therapy*
D004997:Ethinyl Estradiol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone